Publications | PubMed=4567231; DOI=10.1093/jnci/49.3.891 Minowada J., Onuma T., Moore G.E. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J. Natl. Cancer Inst. 49:891-895(1972) PubMed=4547172; DOI=10.1093/jnci/53.3.655 Huang C.C., Hou Y., Woods L.K., Moore G.E., Minowada J. Cytogenetic study of human lymphoid T-cell lines derived from lymphocytic leukemia. J. Natl. Cancer Inst. 53:655-660(1974) PubMed=165156; DOI=10.1002/ijc.2910150217 Nilsson K., Ponten J. Classification and biological nature of established human hematopoietic cell lines. Int. J. Cancer 15:321-341(1975) PubMed=6181032; DOI=10.1016/0198-8859(82)90037-4 Rabinowitz R., Weinstock J., Margalioth E.J., Ben-Bassat H., Schlesinger M. Antigens specific for human T-lymphocytes detected by xenoantisera to HD-MAR cells: their differential expression on various T-cell lines. Hum. Immunol. 4:219-228(1982) PubMed=6954533; DOI=10.1073/pnas.79.7.2194 Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A., Aaronson S.A., Wong-Staal F. Differential expression of the amv gene in human hematopoietic cells. Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982) PubMed=6198871; DOI=10.18926/AMO/32400 Oda T., Watanabe S., Nakamura T. Type C virus particles produced in human T-cell lines derived from acute lymphoblastic leukemia and a leukemic T-lymphoid malignancy. Acta Med. Okayama 37:529-533(1983) PubMed=6200433; DOI=10.1007/BF00364762 Brodsky F.M. A matrix approach to human class II histocompatibility antigens: reactions of four monoclonal antibodies with the products of nine haplotypes. Immunogenetics 19:179-194(1984) PubMed=6582512; DOI=10.1073/pnas.81.2.568 Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O. Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984) PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0 Drexler H.G., Gaedicke G., Minowada J. Isoenzyme studies in human leukemia-lymphoma cell lines -- 1 carboxylic esterase. Leuk. Res. 9:209-229(1985) PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1 Drexler H.G., Gaedicke G., Minowada J. Isoenzyme studies in human leukemia-lymphoma cell lines -- III Beta-hexosaminidase (E.C. 3.2.1.30). Leuk. Res. 9:549-559(1985) PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x Drexler H.G., Gaedicke G., Minowada J. Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase. Leuk. Res. 9:537-548(1985) PubMed=2846092; DOI=10.1182/blood.V72.5.1755.1755 Greenberg J.M., Gonzalez-Sarmiento R., Arthur D.C., Wilkowski C.W., Streifel B.J., Kersey J.H. Immunophenotypic and cytogenetic analysis of Molt-3 and Molt-4: human T-lymphoid cell lines with rearrangement of chromosome 7. Blood 72:1755-1760(1988) PubMed=3335022 Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48:589-601(1988) PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x Nakano A., Harada T., Morikawa S., Kato Y. Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines. Acta Pathol. Jpn. 40:107-115(1990) PubMed=2144611; DOI=10.1128/mcb.10.10.5502-5509.1990 Cheng J., Haas M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol. Cell. Biol. 10:5502-5509(1990) PubMed=1765142; DOI=10.1016/0014-5793(91)81402-t Orita S., Saiga A., Takagi S., Tanaka T., Okumura K., Aono Y., Hinuma Y., Igarashi H. A novel alternatively spliced viral mRNA transcribed in cells infected with human T cell leukemia virus type 1 is mainly responsible for expressing p21X protein. FEBS Lett. 295:127-134(1991) PubMed=2041050; DOI=10.1093/jnci/83.11.757 Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 83:757-766(1991) CLPUB00447 Mulivor R.A., Suchy S.F. 1992/1993 catalog of cell lines. NIGMS human genetic mutant cell repository. 16th edition. October 1992. (In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992) PubMed=8316623; DOI=10.2307/3578190 Evans H.H., Ricanati M., Horng M.-F., Jiang Q.-Y., Mencl J., Olive P.L. DNA double-strand break rejoining deficiency in TK6 and other human B-lymphoblast cell lines. Radiat. Res. 134:307-315(1993) PubMed=8127147 Heyman M., Grander D., Brondum-Nielsen K., Cederblad B., Liu Y., Xu B., Einhorn S. Interferon system defects in malignant T-cells. Leukemia 8:425-434(1994) PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G., Uppenkamp M., Nowrousian M.R., Seeber S., Opalka B. Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines. Br. J. Haematol. 91:350-354(1995) DOI=10.11418/jtca1981.15.4_211 Matsuo Y., Okochi A., Ariyasu T., Iimura E., Ohno T. Identification of cell lines with variable numbers of tandem repeat (VNTR) amplified by polymerase chain reaction. Tissue Cult. Res. Commun. 15:211-219(1996) PubMed=8558913 Morita S., Tsuchiya S., Fujie H., Itano M., Ohashi Y., Minegishi M., Imaizumi M., Endo M., Takano N., Konno T. Cell surface c-kit receptors in human leukemia cell lines and pediatric leukemia: selective preservation of c-kit expression on megakaryoblastic cell lines during adaptation to in vitro culture. Leukemia 10:102-105(1996) PubMed=8641406; DOI=10.1111/j.1600-0609.1996.tb00721.x Borgonovo-Brandter L., Heyman M., Rasool O., Liu Y., Grander D., Einhorn S. p16INK4/p15INK4B gene inactivation is a frequent event in malignant T-cell lines. Eur. J. Haematol. 56:313-318(1996) PubMed=8957066; DOI=10.1111/j.1349-7006.1996.tb03112.x Kawasaki N., Matsuo Y., Yoshino T., Yanai H., Oka T., Teramoto N., Liu C., Kondo E., Minowada J., Akagi T. Metastatic potential of lymphoma/leukemia cell lines in SCID mice is closely related to expression of CD44. Jpn. J. Cancer Res. 87:1070-1077(1996) PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y., Hirai H. Frameshift mutations of the hMSH6 gene in human leukemia cell lines. Jpn. J. Cancer Res. 89:33-39(1998) PubMed=9685479; DOI=10.1093/nar/26.16.3651 Hultdin M., Gronlund E., Norrback K.-F., Eriksson-Lindstrom E., Just T., Roos G. Telomere analysis by fluorescence in situ hybridization and flow cytometry. Nucleic Acids Res. 26:3651-3656(1998) PubMed=9787181; DOI=10.1182/blood.V92.9.3410 Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M. PTEN gene alterations in lymphoid neoplasms. Blood 92:3410-3415(1998) PubMed=10071127; DOI=10.1016/S0145-2126(98)00146-5 Kawamura M., Ohnishi H., Guo S.X., Sheng X.-M., Minegishi M., Hanada R., Horibe K., Hongo T., Kaneko Y., Bessho F., Yanagisawa M., Sekiya T., Hayashi Y. Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia. Leuk. Res. 23:115-126(1999) PubMed=10700174; DOI=10.1038/73432 Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24:227-235(2000) PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4 Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J. Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines. Leuk. Res. 24:255-262(2000) PubMed=11021758; DOI=10.1038/sj.leu.2401891 Majka M., Rozmyslowicz T., Honczarenko M., Ratajczak J., Wasik M.A., Gaulton G.N., Ratajczak M.Z. Biological significance of the expression of HIV-related chemokine coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic cell lines. Leukemia 14:1821-1832(2000) DOI=10.1016/B978-0-12-221970-2.50457-5 Drexler H.G. The leukemia-lymphoma cell line factsbook. (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001) PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1 Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J. Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000),255-262. Leuk. Res. 25:275-278(2001) PubMed=11986953; DOI=10.1038/sj.leu.2402485 O'Donnell P.H., Guo W.-X., Reynolds C.P., Maurer B.J. N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes. Leukemia 16:902-910(2002) PubMed=12068308; DOI=10.1038/nature00766 Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 417:949-954(2002) PubMed=15472075; DOI=10.1126/science.1102160 Weng A.P., Ferrando A.A., Lee W., Morris J.P. IV, Silverman L.B., Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306:269-271(2004) PubMed=15748285; DOI=10.1186/1479-5876-3-11 Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M. HLA class I and II genotype of the NCI-60 cell lines. J. Transl. Med. 3:11.1-11.8(2005) PubMed=15901131; DOI=10.1016/j.prp.2005.01.002 Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y. Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines. Pathol. Res. Pract. 201:109-115(2005) PubMed=16408098; DOI=10.1038/sj.leu.2404081 Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 20:471-476(2006) PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433 Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol. Cancer Ther. 5:2606-2612(2006) PubMed=17117183; DOI=10.1038/sj.bjc.6603447 Beesley A.H., Palmer M.-L., Ford J., Weller R.E., Cummings A.J., Freitas J.R., Firth M.J., Perera K.U., de Klerk N.H., Kees U.R. Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines. Br. J. Cancer 95:1537-1544(2006) PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921 Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N. DNA fingerprinting of the NCI-60 cell line panel. Mol. Cancer Ther. 8:713-724(2009) PubMed=20164919; DOI=10.1038/nature08768 Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R. Signatures of mutation and selection in the cancer genome. Nature 463:893-898(2010) PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458 Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 70:2158-2164(2010) DOI=10.4172/2157-7145.S2-005 Fang R.-X., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M., Hart R.P., Furtado M.R. STR profiling of human cell lines: challenges and possible solutions to the growing problem. J. Forensic Res. 2 Suppl. 2:5-5(2011) PubMed=20922763; DOI=10.1002/pbc.22801 Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J., Reynolds C.P. National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr. Blood Cancer 56:239-249(2011) PubMed=22068913; DOI=10.1073/pnas.1111840108 Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011) PubMed=22347499; DOI=10.1371/journal.pone.0031628 Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C. Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location. PLoS ONE 7:E31628-E31628(2012) PubMed=22384151; DOI=10.1371/journal.pone.0032096 Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T. Identification of cancer cell-line origins using fluorescence image-based phenomic screening. PLoS ONE 7:E32096-E32096(2012) PubMed=22460905; DOI=10.1038/nature11003 Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607(2012) PubMed=22628656; DOI=10.1126/science.1218595 Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336:1040-1044(2012) PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342 Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res. 73:4372-4382(2013) PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018 Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M., Kuster B. Global proteome analysis of the NCI-60 cell line panel. Cell Rep. 4:609-620(2013) PubMed=24279929; DOI=10.1186/2049-3002-1-20 Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A. The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. Cancer Metab. 1:20.1-20.13(2013) PubMed=24670534; DOI=10.1371/journal.pone.0092047 Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C. High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner. PLoS ONE 9:E92047-E92047(2014) PubMed=24762992; DOI=10.7534/j.issn.1009-2137.2014.02.004 Ma X.-C., Liu C.-Y., Sun X.-J., He J.-J., Wan S.-G., Sun W.-L. Genetic characteristics of human acute lymphoblastic leukemia cell line Molt-4. Zhongguo Shi Yan Xue Ye Xue Za Zhi 22:280-284(2014) PubMed=26295583; DOI=10.1371/journal.pone.0135958 Vidyasekar P., Shyamsunder P., Arun R., Santhakumar R., Kapadia N.K., Kumar R., Verma R.S. Genome wide expression profiling of cancer cell lines cultured in microgravity reveals significant dysregulation of cell cycle and microRNA gene networks. PLoS ONE 10:E0135958-E0135958(2015) PubMed=27377824; DOI=10.1038/sdata.2016.52 Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J. Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR. Sci. Data 3:160052-160052(2016) PubMed=27397505; DOI=10.1016/j.cell.2016.06.017 Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J. A landscape of pharmacogenomic interactions in cancer. Cell 166:740-754(2016) PubMed=27807467; DOI=10.1186/s13100-016-0078-4 Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H. A map of mobile DNA insertions in the NCI-60 human cancer cell panel. Mob. DNA 7:20.1-20.11(2016) PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005 Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H. Characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell 31:225-239(2017) PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019) PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019) PubMed=31160637; DOI=10.1038/s41598-019-44491-x Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G. The LL-100 panel: 100 cell lines for blood cancer studies. Sci. Rep. 9:8218-8218(2019) PubMed=32449352; DOI=10.1021/acs.jproteome.0c00254 Cao X.-W., Khitun A., Na Z.-K., Dumitrescu D.G., Kubica M., Olatunji E., Slavoff S.A. Comparative proteomic profiling of unannotated microproteins and alternative proteins in human cell lines. J. Proteome Res. 19:3418-3426(2020) PubMed=35354797; DOI=10.1038/s41467-022-29224-5 Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T., Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E., Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I., Lehtio J., Vesterlund M., Jafari R. Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines. Nat. Commun. 13:1691.1-1691.19(2022) PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010 Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R. Pan-cancer proteomic map of 949 human cell lines. Cancer Cell 40:835-849.e8(2022) |
---|